Inicio › Linfoma de Burkitt › Georgia
Ensayos clínicos de Linfoma de Burkitt en Georgia
11 estudios sobre Linfoma de Burkitt buscan participantes en Georgia.
Ciudades en Georgia
Texto oficial del estudio (inglés)
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT03739814A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- y 1 más
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 28 sept 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 25 sept 2026 · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Augusta University Medical Center, Augusta
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 2 sept 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 1 sept 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- y 1 más
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Atlanta
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Healthcare of Atlanta at Egleston, Atlanta
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Winship Cancer Institute, Emory University, Atlanta
- Augusta Cancer Center, Augusta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Healthcare of Atlanta, Atlanta
ReclutandoFase 2
Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.